Pramod Kumar Srivastava, PhD, MD, is the Northeast Utilities Chair Professor in Experimental Oncology, professor of immunology and medicine, and director of the Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut School of Medicine in Farmington, CT. Dr. Srivastava has championed the cause of personalized Immunotherapy of human cancer for over 25 years. He was the first to demonstrate that immunization of mice with heat-shock proteins (HSP) hsp70 and hsp90 isolated from tumors elicited tumor-specific immunity, and that immunogenicity of tumor-derived HSPs comes from HSP-associated peptides, which include any antigenic peptides. He suggested and showed that hsp70 and hsp90 members play a critical role in antigen processing and presentation by MHC class I molecules. Dr. Srivastava showed that endogenous HSP peptide complexes are the essential vehicles of antigen transfer from antigen-donor cells to antigen-presenting cells (APC) during cross-priming. To explain the powerful adjuvant-like properties of hsp70 and hsp90, he hypothesized and later showed that these HSPs interact with APCs through HSP receptors, such asCD91. Dr. Srivastava developed the HSP-peptide cancer vaccine vitespen or Oncophage, which was approved in Russia in 2008 for treatment of patients with nonmetastatic renal cell carcinoma. Oncophage is the first therapeutic cancer vaccine to be approved for clinical use in the world. An NIH/CTEP (Cancer Therapy Evaluation Program)–approved large randomized study testing Oncophage in patients with recurrent glioblastoma multiforme is ongoing at multiple U.S. centers.
Dr. Srivastava hypothesized in 1993 that cancers are individually antigenically distinct because of random passenger mutations, a proportion of which become immunogenic in any given patient. With the availability of high-throughput genomics and bioinformatics capabilities, he and others have demonstrated that this is indeed the case. Dr. Srivastava is now pursuing genomics-driven personalized immunotherapy for the treatment of human ovarian and other cancers.
Dr. Srivastava has had continuous research support from the NIH for 25 years. He was a member of the NIH Experimental Immunology Study Section and several study sections of the U.S. Department of Defense. He has been a member of the Scientific Advisory Council of the Cancer Research Institute since 1995. In 1997 he was inducted into the Roll of Honor ofthe Union Internationale Contre le Cancer and became a founding member of the Academy of Cancer Immunology. Dr. Srivastava is an inventor on over 200 awarded patents and has cofounded a number of biotechnology companies, including Antigenics (AGEN), Ikonisys, and Life Science Pharmaceuticals.
Dr. Srivastava obtained his bachelor’s degree in biology and chemistry and a master’s degree in botany (paleontology) from the University of Allahabad, India. He studied yeast genetics at Osaka University, Japan, and completed his PhD in biochemistry at the Center for Cellular and Molecular Biology, Hyderabad, India. He also trained at Yale University and Sloan Kettering Institute for Cancer Research. He obtained his MD degree from the University Of Connecticut School of Medicine. He has previously held faculty positions at the Mount Sinai School of Medicine and Fordham University, both in New York City.
Dr. Charles M. Balch has a distinguished 35-year career as an academic oncologist. He is currently a Professor of Surgery at the University of Texas Southwestern Medical Center. Previously the Deputy Director for Clinical Trials and Outcomes Research at Johns Hopkins Institute and Director of the Johns Hopkins Clinical Research Network, Dr. Balch is regarded as one of the world’s leading melanoma and breast cancer experts. In past years, he served as President and CEO of the City of Hope National Medical Center; as Executive Vice President for Health Affairs, Vice President of Hospital and Clinics, and Head of the Division of Surgery, among other positions, at the University of Texas M.D. Anderson Cancer Center; and as Associate Director for Clinical Studies at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center. Now, Dr. Balch works globally to help countries such as China, Japan, and India develop robust cancer research programs and clinical trial groups. His research interests include clinical trials, biological therapy for cancer, sentinel lymph nodes and cancer biomarkers. Dr. Balch is the founding Editor-in-Chief of the Annals of Surgical Oncology, has authored over 700 publications, and has lectured in more than 35 countries and most of the major academic centers in the U.S. Dr. Balch also served in various administrative and leadership positions with the American Society of Clinical Oncology (Executive Vice President and CEO), the Society of Surgical Oncology (President), the American Board of Surgery (Board of Directors and Chair of the Certifying Examination Committee), the Association of Academic Surgeons (President), the Commission on Cancer (Chair, Board of Directors), and the American Joint Committee on Cancer (Executive Committee). He was also on the founding Boards of the National Comprehensive Cancer Network (NCCN) and the National Cancer Data Base (NCDB). A graduate of the University of Toledo, Dr. Balch earned his MD from Columbia University’s College of Physicians and Surgeons.
Dr. Daly currently holds the position of Professor of Surgery at Fox Chase. He was previously the Dean of the Medical School at Temple University School of Medicine, as well as the Atterbury Stimson Professor and Chairman in the Department of Surgery at the Joan and Sanford I. Weill Medical College of Cornell University. He was also the Surgeon-in-Chief at New York Presbyterian Hospital-NY Weill Cornell Center.
He is the author of over 200 peer-reviewed publications and 95 book chapters. Recent peer-reviewed publications include “Oncology” and “Abdominal Wall, Omentum, Mesentery and Retroperitoneum” and “Stomach” chapters in Principles of Surgery, 7th edition, Schwartz et al (eds), McGraw-Hill Companies, Inc. 1999. “Nutrition and the Cancer Patient” in Cancer Surgery for the General Surgeon, Winchester et al (eds), Lippincott Williams & Wilkins 1999. Dr. Daly’s affiliations to medical societies and board memberships are quite extensive. A partial list would include: American Surgical Association, International Surgical Group, American Board of Surgery, American Cancer Society, American Board of Colon and Rectal Surgeons, the Society of Surgical Oncology and the American College of Surgeons.
In addition, he serves on the Editorial Boards of Surgery and the Annals of Surgery. He is also the Editor-in-Chief of Contemporary Surgery, Associate Editor of HPB Surgery and Cancer. He is Editor of Essential Surgical Immunology, Principles of Surgery (7th edition), and the Atlas of Surgical Oncology. His recent honors and awards include: The Best Doctors in New York, The 318 Top Cancer Specialists for Women, Top Cancer Doctors in New York City and The Best Doctors in America. He was the Henry Shenkin Visiting Professor at Temple University Hospital, Distinguished Lecturer at the Royal Academy of Medicine in Ireland, the D. Hayes Agnew Distinguished Lecturer at the University of Pennsylvania Medical Center and the JD Martin Visiting Professor at Emory University School of Medicine. Dr. Daly’s clinical and research interests are in the fields of surgical oncology, metabolism and nutrition.
See a list of all the Management Team at CureVax.View Now